Advertisement

Small Intestine Cancer

  • Pedro Nazareth AguiarJr.
  • Carmelia Maria Noia Barreto
  • Nora Manoukian Forones
  • Hakaru Tadokoro
  • Ramon Andrade De MelloEmail author
Chapter

Abstract

Primary small intestine cancers are not frequent, accounting for <1% of all adult neoplasms. Various histologic types are associated with small intestine cancer. The most common used to be adenocarcinoma; however, carcinoid tumors are showing an improved incidence and are the most common histologic type in some series. Adenocarcinomas are more frequent in the duodenum, while carcinoid tumors are more common in the ileum. Other histologic types are lymphomas and sarcomas. The symptoms are vague and non-specific. Less of an index of suspicious can cause a late the diagnosis. The stage at diagnosis is the most important prognostic factor. Radiologic and endoscopic exams can be performed to achieve a specimen sample and to stage the disease. Early tumors can be treated properly with surgical resection. Adjuvant treatment for adenocarcinoma has not been studied in large trials, but it is indicated in extrapolating colon data. The treatment for advanced adenocarcinoma of the small intestine has only been studied in a few large cohorts. Treatment for other histologic types is discussed in a separated chapter.

Keywords

Small intestine Cancer Chemotherapy 

Abbreviations

GI

Gastrointestinal

UE

Upper Endoscopy

VCE

Video Capsule Endoscopy

CT

Computed Tomography

PET

Positron Emission Tomography

AJCC

American Joint Committee on Cancer

ASCO

American Society of Clinical Oncology

FOLFOX

Fluouracil plus Oxaliplatin

FOLFIRI

Fluouracil plus Irinotecan

PD-1

Programmed-Death Receptor 1

FDA

Food and Drug Administration

ESMO

European Society of Medical Oncology

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29CrossRefGoogle Scholar
  2. 2.
    Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS (2009) Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 249(1):63–71CrossRefGoogle Scholar
  3. 3.
    Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O et al (2008) Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 8:170CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chow WH, Linet MS, McLaughlin JK, Hsing AW, Chien HT, Blot WJ (1993) Risk factors for small intestine cancer. Cancer Causes Control 4(2):163–169CrossRefGoogle Scholar
  5. 5.
    Hatzaras I, Palesty JA, Abir F, Sullivan P, Kozol RA, Dudrick SJ et al (2007) Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry. Arch Surg 142(3):229–235CrossRefGoogle Scholar
  6. 6.
    Haselkorn T, Whittemore AS, Lilienfeld DE (2005) Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control 16(7):781–787CrossRefGoogle Scholar
  7. 7.
    Wheeler JM, Warren BF, Mortensen NJ, Kim HC, Biddolph SC, Elia G et al (2002) An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut 50(2):218–223CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Zhang MQ, Chen ZM, Wang HL (2006) Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol 19(4):573–580CrossRefGoogle Scholar
  9. 9.
    Abrahams NA, Halverson A, Fazio VW, Rybicki LA, Goldblum JR (2002) Adenocarcinoma of the small bowel: a study of 37 cases with emphasis on histologic prognostic factors. Dis Colon Rectum 45(11):1496–1502CrossRefGoogle Scholar
  10. 10.
    Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6):1447–1453CrossRefGoogle Scholar
  11. 11.
    Jess T, Winther KV, Munkholm P, Langholz E, Binder V (2004) Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 19(3):287–293CrossRefGoogle Scholar
  12. 12.
    Wu AH, Yu MC, Mack TM (1997) Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. Int J Cancer 70(5):512–517CrossRefGoogle Scholar
  13. 13.
    Ciresi DL, Scholten DJ (1995) The continuing clinical dilemma of primary tumors of the small intestine. Am Surg 61(8):698–702. discussion -3PubMedGoogle Scholar
  14. 14.
    Howe JR, Karnell LH, Menck HR, Scott-Conner C (1999) The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985–1995. Cancer 86(12):2693–2706CrossRefGoogle Scholar
  15. 15.
    Saha S, Hoda S, Godfrey R, Sutherland C, Raybon K (1989) Carcinoid tumors of the gastrointestinal tract: a 44-year experience. South Med J 82(12):1501–1505CrossRefGoogle Scholar
  16. 16.
    Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W et al (2001) Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 19(18):3861–3873CrossRefGoogle Scholar
  17. 17.
    Maglinte DD, O’Connor K, Bessette J, Chernish SM, Kelvin FM (1991) The role of the physician in the late diagnosis of primary malignant tumors of the small intestine. Am J Gastroenterol 86(3):304–308PubMedGoogle Scholar
  18. 18.
    Zollinger RM (1986) Primary neoplasms of the small intestine. Am J Surg 151(6):654–658CrossRefGoogle Scholar
  19. 19.
    Estrin HM, Farhi DC, Ament AA, Yang P (1987) Ileoscopic diagnosis of malignant lymphoma of the small bowel in acquired immunodeficiency syndrome. Gastrointest Endosc 33(5):390–391CrossRefGoogle Scholar
  20. 20.
    Lewis BS, Eisen GM, Friedman S (2005) A pooled analysis to evaluate results of capsule endoscopy trials. Endoscopy 37(10):960–965CrossRefGoogle Scholar
  21. 21.
    Cobrin GM, Pittman RH, Lewis BS (2006) Increased diagnostic yield of small bowel tumors with capsule endoscopy. Cancer 107(1):22–27CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wiarda BM, Mensink PB, Heine DG, Stolk M, Dees J, Hazenberg H et al (2012) Small bowel Crohn’s disease: MR enteroclysis and capsule endoscopy compared to balloon-assisted enteroscopy. Abdom Imaging 37(3):397–403CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Laurent F, Raynaud M, Biset JM, Boisserie-Lacroix M, Grelet P, Drouillard J (1991) Diagnosis and categorization of small bowel neoplasms: role of computed tomography. Gastrointest Radiol 16(2):115–119CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Pilleul F, Penigaud M, Milot L, Saurin JC, Chayvialle JA, Valette PJ (2006) Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. Radiology 241(3):796–801CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kalady MF, Clary BM, Clark LA, Gottfried M, Rohren EM, Coleman RE et al (2002) Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol 9(8):799–806CrossRefGoogle Scholar
  26. 26.
    Edge S, Byrd D, Compton C et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York. 181 pGoogle Scholar
  27. 27.
    Edge S, Gfeene F, Byrd D, Brookland R, Washington M, Gershenwald J et al (eds) (2017) AJCC American Joint Committee on Cancer Staging Manual, 8th edn. Springer, Chicago. 983 pGoogle Scholar
  28. 28.
    Frost DB, Mercado PD, Tyrell JS (1994) Small bowel cancer: a 30-year review. Ann Surg Oncol 1(4):290–295CrossRefGoogle Scholar
  29. 29.
    DiSario JA, Burt RW, Vargas H, McWhorter WP (1994) Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol 89(5):699–701PubMedGoogle Scholar
  30. 30.
    Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM et al (2000) What prognostic factors are important in duodenal adenocarcinoma? Arch Surg 135(6):635–641. discussion 41–2.CrossRefGoogle Scholar
  31. 31.
    Singhal N, Singhal D (2007) Adjuvant chemotherapy for small intestine adenocarcinoma. Cochrane Database Syst Rev 3:CD005202Google Scholar
  32. 32.
    Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J (2004) Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101(3):518–526CrossRefGoogle Scholar
  33. 33.
    Barnes G, Romero L, Hess KR, Curley SA (1994) Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol 1(1):73–78CrossRefGoogle Scholar
  34. 34.
    Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim MS, Singh G (2010) Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol 17(10):2728–2732CrossRefGoogle Scholar
  35. 35.
    Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA (2010) Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474–479CrossRefGoogle Scholar
  36. 36.
    Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF (2010) A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 199(6):797–803CrossRefGoogle Scholar
  37. 37.
    Haan JC, Buffart TE, Eijk PP, van de Wiel MA, van Wieringen WN, Howdle PD et al (2012) Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancers. Ann Oncol 23(2):367–374CrossRefGoogle Scholar
  38. 38.
    André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116CrossRefGoogle Scholar
  39. 39.
    Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J et al (2008) Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038–2045CrossRefGoogle Scholar
  40. 40.
    Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS et al (2009) Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 27(16):2598–2603CrossRefGoogle Scholar
  41. 41.
    Nakayama N, Horimatsu T, Takagi S, Moriwaki T, Hirashima Y (2014) A phase II study of 5-FU/l-LV/oxaliplatin (mFOLFOX6) in patients with metastatic or unresectable small bowel adenocarcinoma. J Clin Oncol 32(15_suppl):3646CrossRefGoogle Scholar
  42. 42.
    Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E et al (2010) Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 21(9):1786–1793CrossRefGoogle Scholar
  43. 43.
    Zaanan A, Gauthier M, Malka D, Locher C, Gornet JM, Thirot-Bidault A et al (2011) Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 117(7):1422–1428CrossRefGoogle Scholar
  44. 44.
    Sun Y, Shen P, Stewart JH, Russell GB, Levine EA (2013) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. Am Surg 79(6):644–648PubMedPubMedCentralGoogle Scholar
  45. 45.
    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26028255
  46. 46.
    Aguiar PN, Tadokoro H, Forones NM, de Mello RA (2015) MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer. Immunotherapy 7(11):1133–1134. [Internet]. Available from: http://www.futuremedicine.com/doi/10.2217/imt.15.84CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409–413. [Internet]. NIH Public Access; [cited 2017 Oct 9]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/28596308CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A et al (2013) Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi64–vi72CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Pedro Nazareth AguiarJr.
    • 1
  • Carmelia Maria Noia Barreto
    • 2
  • Nora Manoukian Forones
    • 3
  • Hakaru Tadokoro
    • 4
  • Ramon Andrade De Mello
    • 5
    • 6
    Email author
  1. 1.Faculdade de Medicina do ABCSanto AndréBrazil
  2. 2.Instituto Avanços em MedicinaSão PauloBrazil
  3. 3.Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP)São PauloBrazil
  4. 4.Division of Medical Oncology, Escola Paulista de MedicinaFederal University of São PauloSão PauloBrazil
  5. 5.Division of Medical OncologyFederal University of São Paulo (UNIFESP) & Hospital Israelita Albert EinsteinSão PauloBrazil
  6. 6.Department of Biomedical Sciences and MedicineUniversity of AlgarveFaroPortugal

Personalised recommendations